BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q4 2024 Earnings Call Transcript February 24, 2025
BioCryst Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.13 EPS, expectations were $-0.07.
Operator: Good morning, and welcome to the BioCryst Fourth Quarter 2024 Earnings Call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing star then zero on your telephone keypad. After today’s presentation,...
